Shareholders Equity (Quarterly)

Shareholders Equity: The sum of preferred and common equity items.

Syndax Pharmaceuticals, Inc. (SNDX) had Shareholders Equity of $115.43M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$45.87M
Net Income	$-60.72M
Cost of Goods Sold	$2.10M
Gross Profit	$43.77M
Operating Expenses	$103.30M
Operating Income	$-57.43M
Non-Operating Income/Expense	$-3.29M
Pre-Tax Income	$-60.72M
Normalized Pre-Tax Income	$-60.72M
Income after Taxes	$-60.72M
Income from Continuous Operations	$-60.72M
Consolidated Net Income/Loss	$-60.72M
Normalized Income after Taxes	$-60.72M
EBIT	$-57.43M
EBITDA	$-59.77M
Weighted-Average Shares Outstanding (Basic)	86.62M
Weighted-Average Shares Outstanding (Diluted)	86.62M
Earnings per Share (EPS) (Basic)	$-0.70
Earnings per Share (EPS) (Diluted)	$-0.70
Balance Sheet Financials
Current Assets	$529.83M
Property, Plant, and Equipment	$0.13M
Long-Term Assets	$21.96M
Total Assets	$551.79M
Current Liabilities	$114.19M
Long-Term Debt	$320.99M
Long-Term Liabilities	$322.18M
Total Liabilities	$436.36M
Common Equity	$115.43M
Tangible Shareholders Equity	$115.43M
Shareholders Equity	$115.43M
Common Shares Outstanding	86.91M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-253.49M
Cash Flow from Investing Activities	$208.46M
Cash Flow from Financial Activities	$7.76M
Beginning Cash	$154.30M
End Cash	$117.03M
Increase/Decrease in Cash	$-37.27M
Stock-Based Compensation	$36.25M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.64
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.74
Debt to Equity Ratio	2.98
Gross Margin	95.42%
Operating Margin	-125.19%
EBIT Margin	-125.19%
EBITDA Margin	--
Pre-Tax Profit Margin	-132.36%
Profit Margin	-132.36%
Free Cash Flow	$-253.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.08
Receiveable Turnover	1.11
Days Sales in Receivables	80.72
Return on Equity	-52.60%
Return on Tangible Equity	-52.60%
Return on Assets	-11.00%
Return on Investments	-13.91%
Book Value Per Share	$1.33
Free Cash Flow per Share	$-2.93
Operating Cash Flow per Share	$-2.93

Data from Zacks Investment Research, Inc.